Peptides for skin, hair and tanning

In animals, GHK-Cu is consistently helpful. In a 2003 University of Florida study, rat wounds cut into skin with deliberately poor blood supply shrank by 64.5 percent in thirteen days with a GHK-Cu gel, against 45.6 percent with the gel base and 28.2 percent untreated. The treated wounds also held less TNF-alpha, a key inflammatory signal, and less of the matrix-dissolving enzymes that are overactive in wounds that refuse to close.

Human trials split down the middle. In a 1994 randomized, evaluator-blinded trial in diabetic foot ulcers, a GHK-Cu gel on top of careful standard care closed a median 98.5 percent of ulcer area, against 60.8 percent with the inactive gel, and infections fell from 34 to 7 percent. Two years earlier, a randomized trial in 86 people with venous leg ulcers found a copper tripeptide cream did no better than placebo. Different wounds, different formulations, opposite answers.

The cosmetic data are thinner still. In a 2006 randomized trial, people recovering from laser resurfacing around the mouth used aftercare with or without GHK-Cu. Blinded evaluators and computer analysis found no difference in redness, wrinkles or skin quality at twelve weeks. The GHK-Cu group did rate their own skin as more improved. Only 13 people finished, so the study settles nothing, but it shows how far the feel of skin and its measurement can drift apart.

One more caution matters. Nearly everything known about GHK-Cu in people comes from creams and gels. Injected GHK-Cu has no published human trials over months, and that is a different product with a different risk profile.^7891029

Melanotan I has the most interesting result in the whole field. In a 2006 Sydney trial of 65 volunteers, the peptide raised melanin in everyone who received it, and it raised it most in those who had the least to begin with: 41 percent in people who burn easily, 12 percent in people who already tan well. When fair-skinned volunteers were then exposed to three times the ultraviolet light that burns them, sunburn cells fell by more than half and DNA damage in the deepest layer of the outer skin fell by 59 percent.

Chemically, Melanotan I and afamelanotide are the same peptide. As a slow-release implant called Scenesse, afamelanotide was tested in two randomized trials in erythropoietic protoporphyria, an inherited disease in which sunlight causes severe pain. In the US trial, median pain-free time in direct sun over six months was 69.4 hours with the drug against 40.8 with placebo. A 2015 vitiligo trial also found faster repigmentation when afamelanotide was added to light therapy, most clearly in darker skin.

Melanotan II is the opposite case. Its controlled human record for tanning is a 1996 pilot in which two of three men got darker. Because it opens several melanocortin receptors, the same men had spontaneous erections, yawning and nausea. Since then, case reports have described sudden crops of new moles, melanoma arising in existing moles, priapism, rhabdomyolysis, kidney infarction and a brain swelling syndrome in people who bought it online. Case reports cannot say how often these happen, only that they do.

Both melanotans darken moles as well as normal skin. The Scenesse label asks for a full-body skin exam twice a year, and a 2017 dermatology review found four reports of melanoma arising from existing moles during or soon after melanotan use, while stressing that a causal link is unproven.^{1514161727181921222324252620}

Skin is a readout of whole-body chemistry, so the strongest levers sit outside any peptide. Ultraviolet light is the largest one. The melanotan trials are a reminder that a sun tan is a receipt for DNA damage already done, which is why sun protection does more for collagen than anything you add afterward.

Blood sugar is the quiet one. Glucose sticks to collagen fibers and cross-links them, a process called glycation, which stiffens skin. HbA1c, your average blood sugar over about three months, shows whether that process is running hot. hs-CRP measures low-grade inflammation anywhere in the body, and many of GHK-Cu’s reported effects involve calming inflammatory signals, so a baseline gives context.

Zinc and copper compete for absorption. Adding a copper complex to a body already short on zinc tilts that balance further, so zinc is worth knowing. Vitamin D belongs on the list for anyone who avoids the sun after a skin scare. For the tanning peptides, the most important check is a dermatologist mapping your moles.

At Vitals Vault, peptide care starts with a blood panel at Quest Diagnostics. A licensed clinician reviews the results with your history, and the same markers are retested later so you can see what changed.^4152720

The skin peptides split cleanly by evidence. Melanotan I, as afamelanotide, has randomized trials and an approval for one painful disease, plus a striking result showing a sunless tan that protected fair skin from some DNA damage. GHK-Cu has elegant biology, a collagen repair signal built into collagen itself, and a handful of small topical trials that disagree. Melanotan II has a clear effect and a long list of case-report harms.

If better skin is the goal, start with the rate of damage before the rate of repair. Ask a clinician what is breaking your collagen down faster than you rebuild it, whether that is sun, blood sugar or inflammation, and what your labs say about it. Once that is answered, you will know whether a repair message still has work to do.^151658920